Freeline Therapeutics Trading Up 14.7 %
Shares of NASDAQ:FRLN opened at $5.76 on Tuesday. The firm has a 50 day simple moving average of $4.43 and a 200-day simple moving average of $3.77. The company has a market capitalization of $25.00 million, a PE ratio of -0.69 and a beta of 0.39. Freeline Therapeutics has a twelve month low of $2.11 and a twelve month high of $10.20.
Institutional Trading of Freeline Therapeutics
Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of Freeline Therapeutics in the first quarter valued at about $30,000. Northern Trust Corp purchased a new position in shares of Freeline Therapeutics in the 2nd quarter valued at approximately $40,000. Federated Hermes Inc. raised its stake in shares of Freeline Therapeutics by 50.0% during the first quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Freeline Therapeutics by 17.4% during the first quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock worth $105,000 after purchasing an additional 34,210 shares during the last quarter. Finally, UBS Group AG acquired a new stake in shares of Freeline Therapeutics during the first quarter worth $565,000. Institutional investors and hedge funds own 46.26% of the company’s stock.
Analyst Ratings Changes
About Freeline Therapeutics
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.
- Five stocks we like better than Freeline Therapeutics
- What is an Earnings Surprise?
- Safeguard your portfolio with these three bargain stocks
- 3 Healthcare Dividend Stocks to Buy
- Membership clubs gain leverage for the consumer rebound
- What is a Special Dividend?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.